Protein misfolding in neurodegenerative diseases

被引:96
|
作者
Agorogiannis, EI [1 ]
Agorogiannis, GI [1 ]
Papadimitriou, A [1 ]
Hadjigeorgiou, GM [1 ]
机构
[1] Univ Thessaly Med Sch, Dept Neurol & Neurogenet, Larisa 41222, Greece
关键词
Alzheimer's disease; chaperones; Huntington's disease; misfolding; Parkinson's disease; proteasome; protofibrils; ubiquitin;
D O I
10.1111/j.1365-2990.2004.00558.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
A common pathogenic mechanism shared by diverse neurodegenerative disorders, like Alzheimer's disease, Parkinson's disease, Huntington's disease and transmissible spongiform encephalopathies, may be altered protein homeostasis leading to protein misfolding and aggregation of a wide variety of different proteins in the form of insoluble fibrils. Mutations in the genes encoding protein constituents of these aggregates have been linked to the corresponding diseases, thus a reasonable scenario of pathogenesis was based on misfolding of a neurone-specific protein that forms insoluble fibrils that subsequently kill neuronal cells. However, during the past 5 years accumulating evidence has revealed the neurotoxic role of prefibrillar intermediate forms (soluble oligomers and protofibrils) produced during fibril formation. Many think these may be the predominant neurotoxic species, whereas microscopically visible fibrillar aggregates may not be toxic. Large protein aggregates may rather be simply inactive, or even represent a protective state that sequesters and inactivates toxic oligomers and protofibrils. Further understanding of the biochemical mechanisms involved in protein misfolding and fibrillization may optimize the planning of common therapeutic approaches for neurodegenerative diseases, directed towards reversal of protein misfolding, blockade of protein oligomerization and interference with the action of toxic proteins.
引用
收藏
页码:215 / 224
页数:10
相关论文
共 50 条
  • [31] The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases
    Winklhofer, Konstanze F.
    Tatzelt, Joerg
    Haass, Christian
    EMBO JOURNAL, 2008, 27 (02): : 336 - 349
  • [32] Bridging the gap: From protein misfolding to protein misfolding diseases
    Luheshi, Leila M.
    Dobson, Christopher M.
    FEBS LETTERS, 2009, 583 (16): : 2581 - 2586
  • [33] S-Nitrosylation of Critical Protein Thiols Mediates Protein Misfolding and Mitochondrial Dysfunction in Neurodegenerative Diseases
    Nakamura, Tomohiro
    Lipton, Stuart A.
    ANTIOXIDANTS & REDOX SIGNALING, 2011, 14 (08) : 1479 - 1492
  • [34] Protein misfolding and medicinal strategies in neurodegenerative disorders
    Mehboudi, Leila
    Zahedirad, Mehrshad
    Vadiei, Parisa
    MEDICINA BALEAR, 2022, 37 (04): : 166 - 170
  • [35] Protein folding and misfolding in the neurodegenerative disorders: A review
    Boshette, N. B.
    Thakur, K. K.
    Bidkar, A. P.
    Trandafir, C.
    Kumar, P.
    Gogoi, R.
    REVUE NEUROLOGIQUE, 2014, 170 (03) : 151 - 161
  • [36] Drugs for protein misfolding diseases
    Katharine H. Wrighton
    Nature Reviews Molecular Cell Biology, 2015, 16 (6) : 328 - 328
  • [37] Protein misfolding and prion diseases
    Cohen, FE
    JOURNAL OF MOLECULAR BIOLOGY, 1999, 293 (02) : 313 - 320
  • [38] Nanoimaging for protein misfolding diseases
    Lyubchenko, Y.
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2006, 2 (04) : 270 - 270
  • [39] Proteomics in protein misfolding diseases
    Stoppini, Monica
    Obici, Laura
    Lavatelli, Francesca
    Giorgetti, Sofia
    Marchese, Loredana
    Moratti, Remigio
    Bellotti, Vittorio
    Merlini, Giampaolo
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2009, 47 (06) : 627 - 635
  • [40] Nanoimaging for protein misfolding diseases
    Lyubchenko, Yuri L.
    Kim, Bo-Hyun
    Krasnoslobodtsev, Alexey V.
    Yu, Junping
    WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2010, 2 (05) : 526 - 543